|
Geerts WH, Bergqvist D, Pineo GF, et al.Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition).Chest 2008; 133:381-453.
|
|
White RH, Keenan CR.Effects of race and ethnicity on the incidence of venous thromboembolism.Thromb Res 2009; 123 Suppl 4:S11-7.
|
|
Piovella F, Wang CJ, Lu H, et al.Deep-vein thrombosis rates after major orthopedic surgery in Asia.An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography.J Thromb Haemost 2005; 3:2664-70.
|
|
Leizorovicz A.Epidemiology of post-operative venous thromboembolism in Asian patients.Results of the SMART venography study.Haematologica 2007; 92:1194-200.
|
|
Cohen AT.Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery.Thromb Haemost 2010; 104:919-30.
|
|
American Academy of Orthopedic Surgeons (US).Guideline on preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty [2011-12-10].http://www.aaos.org/research/guidelines/ VTE/VTE_guideline.asp.
|
|
Struijk-Mulder MC, Ettema HB, Verheyen CC, et al.Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery.J Thromb Haemost 2010; 8:678- 83.
|
|
Raskob GE, Hirsh J.Controversies in timing of the first dose of anticoagulant prophylaxis against venous throm- boembolism after major orthopedic surgery.Chest 2003; 124:379-85.
|
|
Guidelines for prevention of venous thromboembolism after major orthopedic surgery (draft).Chin J Orthop 2007; 27:790-2.
|
|
Froimson MI, Murray TG, Fazekas AF.Venous thromboembolic disease reduction with a portable pneumatic compression device.J Arthroplasty 2009; 24:310-6.
|
|
Friedman RJ, Gallus A, Gil-Garay E, et al.Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty—insights from the Multinational Global Orthopaedic Registry (GLORY).Am J Orthop (Belle Mead NJ) 2010; 39:14-21.
|
|
Salvati EA, Sharrock NE, Westrich G, et al.The 2007 ABJS Nicolas Andry Award: three decades of clinical, basic, and applied research on thromboembolic disease after THA: rationale and clinical results of a multimodal prophylaxis protocol.Clin Orthop Relat Res 2007; 459:246-54.
|
|
Dorr LD, Gendelman V, Maheshwari AV, et al.Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.J Bone Joint Surg Am 2007; 89:2648-57.
|
|
Sugano N, Miki H, Nakamura N, et al.Clinical efficacy of mechanical thromboprophylaxis without anticoagulant drugs for elective hip surgery in an Asian population.J Arthroplasty 2009; 24:1254-7.
|
|
Yokote R, Matsubara M, Hirasawa N, et al.Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? J Bone Joint Surg Br 2011; 93:251-6.
|
|
Mavalankar AP, Majmundar D, Rani S.Routine chemoprophylaxis for deep venous thrombosis in Indian patients: Is it really justified? Indian J Orthop 2007; 41:188-93.
|
|
Strebel N, Prins M, Agnelli G, et al.Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162:1451-6.
|
|
Hull RD, Pineo GF, Francis C, et al.Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs.warfarin in hip arthroplasty patients: a double-blind, randomized comparison.The North American Fragmin Trial Investigators.Arch Intern Med 2000; 160:2199-207.
|
|
Hull RD, Pineo GF, Stein PD, et al.Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.Arch Intern Med 2001; 161:1952-60.
|
|
Eikelboom JW, Quinlan DJ, Douketis JD.Extended-dur- ation prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.Lancet 2001; 358:9-15.
|
|
Cohen AT, Bailey CS, Alikhan R, et al.Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty—a meta-analysis.Thromb Haemost 2001; 85:940-1.
|
|
Muntz J.Duration of deep vein thrombosis prophylaxis in the surgical patient and its relation to quality issues.Am J Surg 2010; 200:413-21.
|
|
Merli GJ, Malangone E, Lin J, et al.Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: an analysis of an integrated healthcare database.J Thromb Thrombolysis 2011; 32:89-95.
|
|
Amin A, Spyropoulos AC, Dobesh P, et al.Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start).J Thromb Thrombolysis 2010; 29:326-39.
|
|
Tribout B, Colin-Mercier F.New versus established drugs in venous thromboprophylaxis: efficacy and safety considerations related to timing of administration.Am J Cardiovasc Drugs 2007; 7:1-15.
|
|
Gordois A, Posnett J, Borris L, et al.The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.J Thromb Haemost 2003; 1:2167-74.
|
|
Matzsch T.Thromboprophylaxis with low-molecular-wei- ght heparin: economic considerations.Haemostasis 2000; 30 Suppl 2:141-5; discussion 128-9.
|
|
Schulman S, Kearon C.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost 2005; 3: 692-4.
|
|
Soff GA.A new generation of oral direct anticoagulants.Arterioscler Thromb Vasc Biol 2012; 32:569-74.
|